IL124551A - Pharmaceutical depot formulations comprising aqueous suspensions of 9-hydroxy risperidone fatty acid esters - Google Patents

Pharmaceutical depot formulations comprising aqueous suspensions of 9-hydroxy risperidone fatty acid esters

Info

Publication number
IL124551A
IL124551A IL12455197A IL12455197A IL124551A IL 124551 A IL124551 A IL 124551A IL 12455197 A IL12455197 A IL 12455197A IL 12455197 A IL12455197 A IL 12455197A IL 124551 A IL124551 A IL 124551A
Authority
IL
Israel
Prior art keywords
fatty acid
acid esters
aqueous suspensions
depot formulations
pharmaceutical depot
Prior art date
Application number
IL12455197A
Other languages
English (en)
Other versions
IL124551A0 (en
Original Assignee
Janssen Pharmaceutica Nv
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Family has litigation
First worldwide family litigation filed litigation Critical https://patents.darts-ip.com/?family=8224016&utm_source=google_patent&utm_medium=platform_link&utm_campaign=public_patent_search&patent=IL124551(A) "Global patent litigation dataset” by Darts-ip is licensed under a Creative Commons Attribution 4.0 International License.
Application filed by Janssen Pharmaceutica Nv filed Critical Janssen Pharmaceutica Nv
Publication of IL124551A0 publication Critical patent/IL124551A0/xx
Publication of IL124551A publication Critical patent/IL124551A/xx

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
    • A61K31/505—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/0012—Galenical forms characterised by the site of application
    • A61K9/0019—Injectable compositions; Intramuscular, intravenous, arterial, subcutaneous administration; Compositions to be administered through the skin in an invasive manner
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
    • A61K31/505—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim
    • A61K31/517—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim ortho- or peri-condensed with carbocyclic ring systems, e.g. quinazoline, perimidine
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/18—Antipsychotics, i.e. neuroleptics; Drugs for mania or schizophrenia
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/22—Anxiolytics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/24—Antidepressants
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/28—Drugs for disorders of the nervous system for treating neurodegenerative disorders of the central nervous system, e.g. nootropic agents, cognition enhancers, drugs for treating Alzheimer's disease or other forms of dementia
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/02—Inorganic compounds
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/06—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite
    • A61K47/08—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite containing oxygen, e.g. ethers, acetals, ketones, quinones, aldehydes, peroxides
    • A61K47/10—Alcohols; Phenols; Salts thereof, e.g. glycerol; Polyethylene glycols [PEG]; Poloxamers; PEG/POE alkyl ethers
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/06—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite
    • A61K47/26—Carbohydrates, e.g. sugar alcohols, amino sugars, nucleic acids, mono-, di- or oligo-saccharides; Derivatives thereof, e.g. polysorbates, sorbitan fatty acid esters or glycyrrhizin
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/30—Macromolecular organic or inorganic compounds, e.g. inorganic polyphosphates
    • A61K47/36—Polysaccharides; Derivatives thereof, e.g. gums, starch, alginate, dextrin, hyaluronic acid, chitosan, inulin, agar or pectin
    • A61K47/38—Cellulose; Derivatives thereof

Landscapes

  • Health & Medical Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • Veterinary Medicine (AREA)
  • Chemical & Material Sciences (AREA)
  • Public Health (AREA)
  • General Health & Medical Sciences (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Biomedical Technology (AREA)
  • Neurosurgery (AREA)
  • Neurology (AREA)
  • Epidemiology (AREA)
  • Organic Chemistry (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Psychiatry (AREA)
  • Dermatology (AREA)
  • Hospice & Palliative Care (AREA)
  • Pain & Pain Management (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Medicinal Preparation (AREA)
  • Organic Low-Molecular-Weight Compounds And Preparation Thereof (AREA)
  • Nitrogen Condensed Heterocyclic Rings (AREA)
  • Agricultural Chemicals And Associated Chemicals (AREA)
IL12455197A 1996-05-20 1997-05-12 Pharmaceutical depot formulations comprising aqueous suspensions of 9-hydroxy risperidone fatty acid esters IL124551A (en)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
EP96201429 1996-05-20
PCT/EP1997/002504 WO1997044039A1 (en) 1996-05-20 1997-05-12 Aqueous suspensions of 9-hydroxyrisperidone fatty acid esters

Publications (2)

Publication Number Publication Date
IL124551A0 IL124551A0 (en) 1998-12-06
IL124551A true IL124551A (en) 2001-08-26

Family

ID=8224016

Family Applications (1)

Application Number Title Priority Date Filing Date
IL12455197A IL124551A (en) 1996-05-20 1997-05-12 Pharmaceutical depot formulations comprising aqueous suspensions of 9-hydroxy risperidone fatty acid esters

Country Status (37)

Country Link
US (1) US6077843A (cs)
EP (1) EP0904081B1 (cs)
JP (1) JP3274687B2 (cs)
KR (1) KR100358373B1 (cs)
CN (1) CN1093762C (cs)
AR (1) AR007194A1 (cs)
AT (1) ATE208619T1 (cs)
AU (1) AU715572B2 (cs)
BG (1) BG62684B1 (cs)
BR (1) BR9706824B8 (cs)
CA (1) CA2236691C (cs)
CY (2) CY2270B1 (cs)
CZ (1) CZ291284B6 (cs)
DE (2) DE69708284T2 (cs)
DK (1) DK0904081T3 (cs)
EA (1) EA000536B1 (cs)
EE (1) EE03594B1 (cs)
ES (1) ES2167745T3 (cs)
FR (1) FR11C0035I2 (cs)
HR (1) HRP970276B1 (cs)
HU (2) HU224025B1 (cs)
ID (1) ID16927A (cs)
IL (1) IL124551A (cs)
LU (1) LU91842I2 (cs)
MX (1) MX9804816A (cs)
MY (1) MY126302A (cs)
NO (2) NO315931B1 (cs)
NZ (1) NZ330369A (cs)
PL (1) PL188309B1 (cs)
PT (1) PT904081E (cs)
SI (1) SI0904081T1 (cs)
SK (1) SK284013B6 (cs)
TR (1) TR199800923T2 (cs)
TW (1) TW487572B (cs)
UA (1) UA61898C2 (cs)
WO (1) WO1997044039A1 (cs)
ZA (1) ZA974331B (cs)

Families Citing this family (51)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
UA72189C2 (uk) * 1997-11-17 2005-02-15 Янссен Фармацевтика Н.В. Фармацевтична композиція, що містить водну суспензію субмікронних ефірів 9-гідроксирисперидон жирних кислот
WO1999043300A1 (en) * 1998-02-25 1999-09-02 Abbott Laboratories Butorphanol sustained release formulations
US6342488B1 (en) * 1998-08-18 2002-01-29 Sepracor, Inc. Phosphonorisperidone and sulforisperidone compositions and methods
EA005291B1 (ru) 1999-03-31 2004-12-30 Янссен Фармацевтика Н.В. Применение предварительно желатинированного крахмала в композиции с контролируемым высвобождением
US6495164B1 (en) * 2000-05-25 2002-12-17 Alkermes Controlled Therapeutics, Inc. I Preparation of injectable suspensions having improved injectability
PL365608A1 (en) * 2000-08-14 2005-01-10 Teva Pharmaceutical Industries Ltd. Preparation of risperidone
US7666445B2 (en) * 2000-10-20 2010-02-23 The Trustees Of The University Of Pennsylvania Polymer-based surgically implantable haloperidol delivery systems and methods for their production and use
GB0216416D0 (en) * 2002-07-15 2002-08-21 Novartis Ag Organic compounds
US20050232995A1 (en) 2002-07-29 2005-10-20 Yam Nyomi V Methods and dosage forms for controlled delivery of paliperidone and risperidone
HRP20050077B1 (hr) * 2002-07-29 2013-11-22 Alza Corporation Postupci i oblici doziranja za kontrolirano oslobađanje paliperidona
GB0322994D0 (en) * 2003-10-01 2003-11-05 Novartis Ag Organic compounds
EP1675573B2 (en) 2003-10-23 2012-06-13 Otsuka Pharmaceutical Co., Ltd. Controlled release sterile injectable aripiprazole formulation and method
US8329203B2 (en) * 2004-01-12 2012-12-11 The Trustees Of The University Of Pennsylvania Drug-containing implants and methods of use thereof
JP5306599B2 (ja) * 2004-01-12 2013-10-02 ザ トラスティーズ オブ ザ ユニバーシティ オブ ペンシルバニア 長期間送達製剤
US8221778B2 (en) 2005-01-12 2012-07-17 The Trustees Of The University Of Pennsylvania Drug-containing implants and methods of use thereof
ES2245252B1 (es) * 2004-06-15 2007-03-01 Farmalider, S.A. Solucion acuosa de risperidona para administracion oral.
US11246913B2 (en) 2005-02-03 2022-02-15 Intarcia Therapeutics, Inc. Suspension formulation comprising an insulinotropic peptide
JP5249748B2 (ja) 2005-04-25 2013-07-31 ジヤンセン・フアーマシユーチカ・ナームローゼ・フエンノートシヤツプ 無菌３−［２−［４−（６−フルオロ−１，２−ベンズイソオキサゾール−３−イル）−１−ピペリジニル］エチル］−６，７，８，９−テトラヒドロ−９−ヒドロキシ−２−メチル−４Ｈ−ピリド［１，２−ａ］ピリミジン−４−オンパルミチン酸エステルの製造
PL116330U1 (en) * 2005-10-31 2007-04-02 Alza Corp Method for the reduction of alcohol provoked rapid increase in the released dose of the orally administered opioide with prolonged liberation
EP2363112B8 (en) 2006-08-09 2018-11-21 Intarcia Therapeutics, Inc. Osmotic delivery systems and piston assemblies
RU2459824C2 (ru) * 2007-04-19 2012-08-27 Юсинь ЛИ Новые соединения для лечения психических расстройств, их получение и применение
PL2157967T3 (pl) 2007-04-23 2013-06-28 Intarcia Therapeutics Inc Formulacje zawiesinowe peptydów insulinotropowych i ich zastosowania
US20090076035A1 (en) * 2007-09-15 2009-03-19 Protia, Llc Deuterium-enriched paliperidone
KR102163196B1 (ko) 2007-12-19 2020-10-12 얀센 파마슈티카 엔.브이. 장기 작용성 주사가능 팔리페리돈 에스테르와 관련된 투여 요법
US20090209757A1 (en) * 2008-01-10 2009-08-20 Santiago Ini Processes for the preparation and purification of paliperidone palmitate
US8343140B2 (en) 2008-02-13 2013-01-01 Intarcia Therapeutics, Inc. Devices, formulations, and methods for delivery of multiple beneficial agents
PL2341905T5 (pl) 2008-09-04 2024-01-15 Amylin Pharmaceuticals, Llc Preparaty o przedłużonym uwalnianiu z wykorzystaniem niewodnych nośników
CN102686741B (zh) 2009-09-28 2018-01-19 精达制药公司 基本稳态药物递送的快速建立和/或终止
EP2493473A1 (en) 2009-10-30 2012-09-05 Janssen Pharmaceutica NV Dosing regimen associated with long-acting injectable paliperidone esters
WO2011074017A1 (en) * 2009-12-17 2011-06-23 Alkem Laboratories Ltd. A novel process for the preparation of paliperidone
TWI577377B (zh) 2010-09-16 2017-04-11 Ｖｉｉｖ醫療保健公司 醫藥組合物
CA2814840C (en) 2010-10-18 2018-08-28 Dainippon Sumitomo Pharma Co., Ltd. Sustained-release formulation for injection
US20120208755A1 (en) 2011-02-16 2012-08-16 Intarcia Therapeutics, Inc. Compositions, Devices and Methods of Use Thereof for the Treatment of Cancers
EP2683717B1 (en) * 2011-05-31 2016-05-25 Ramamohan Rao, Davuluri Preparation of 3-[2-[4-((6-fluoro-1, 2-benzisoxazol-3-yl)-l-piperidinyl)-6, 7, 8, 9-tetrahydro-9-hydroxy-2-methyl-4h-pyrido[ 1, 2-a]-pyrimidin-4-one (paliperidone) and paliperidone palmitate.
WO2013046225A2 (en) * 2011-08-10 2013-04-04 Glenmark Generics Limited Process for the preparation of paliperidone palmitate
CN102993200B (zh) * 2011-09-10 2016-02-03 鲁翠涛 帕潘立酮氨基酸酯及其制备方法
US20140206667A1 (en) 2012-11-14 2014-07-24 Michela Gallagher Methods and compositions for treating schizophrenia
US10525057B2 (en) 2013-09-24 2020-01-07 Otsuka Pharmaceutical Co., Ltd. Method of providing aripiprazole to patients having impaired CYP2D6 or CYP3A4 enzyme function
US9889085B1 (en) 2014-09-30 2018-02-13 Intarcia Therapeutics, Inc. Therapeutic methods for the treatment of diabetes and related conditions for patients with high baseline HbA1c
SI3744326T1 (sl) 2015-04-07 2024-02-29 Janssen Pharmaceutica Nv Shema odmerjanja za izpuščene odmerke za dolgodelujoče estre paliperidona za injiciranje
ES2968262T3 (es) 2015-06-03 2024-05-08 I2O Therapeutics Inc Sistemas de colocación de implantes
KR102574993B1 (ko) 2016-05-16 2023-09-06 인타르시아 세라퓨틱스 인코포레이티드 글루카곤-수용체 선택적 폴리펩티드 및 이들의 이용 방법
USD860451S1 (en) 2016-06-02 2019-09-17 Intarcia Therapeutics, Inc. Implant removal tool
USD840030S1 (en) 2016-06-02 2019-02-05 Intarcia Therapeutics, Inc. Implant placement guide
KR20190104039A (ko) 2017-01-03 2019-09-05 인타르시아 세라퓨틱스 인코포레이티드 Glp-1 수용체 효능제의 연속적인 투여 및 약물의 동시-투여를 포함하는 방법
AU2021386450B2 (en) 2020-11-30 2024-03-21 Janssen Pharmaceutica Nv Dosing regimens associated with extended release paliperidone injectable formulations
TWI838623B (zh) 2020-11-30 2024-04-11 比利時商健生藥品公司 與延釋帕利哌酮可注射配製物相關之投藥方案（二）
ES2983033T3 (es) 2020-11-30 2024-10-21 Janssen Pharmaceutica Nv Métodos para garantizar la resuspensión de formulaciones de palmitato de paliperidona
WO2022111860A1 (en) 2020-11-30 2022-06-02 Janssen Pharmaceutica Nv Dosing regimens associated with extended release paliperidone injectable formulations
HUP2100259A1 (hu) 2021-07-07 2023-01-28 Richter Gedeon Nyrt Cariprazine tartalmú szabályozott hatóanyag-leadású injekciós készítmények
AU2022329095A1 (en) 2021-08-20 2024-04-04 Janssen Pharmaceutica Nv Dosing regimens associated with extended release paliperidone injectable formulations

Family Cites Families (9)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US5158952A (en) * 1988-11-07 1992-10-27 Janssen Pharmaceutica N.V. 3-[2-[4-(6-fluoro-1,2-benzisoxozol-3-yl)-1-piperidinyl]ethyl]-6,7,8,9 tetrahydro-9-hydroxy-2-methyl-4H-pyrido [1,2-a]pyrimidin-4-one, compositions and method of use
US5254556A (en) * 1988-11-07 1993-10-19 Janssen Pharmaceutica N.V. 3-piperidinyl-1,2-benzisoxazoles
CA2000786C (en) * 1988-11-07 1999-01-26 Cornelus G. M. Janssen 3-piperidinyl-1,2-benzisoxazoles
TW376319B (en) * 1993-04-28 1999-12-11 Janssen Pharmaceutica Nv Pharmaceutical composition containing risperidone pamoate and having a long acting activity for treating psychoses induced by the release of dopamine
US5650173A (en) * 1993-11-19 1997-07-22 Alkermes Controlled Therapeutics Inc. Ii Preparation of biodegradable microparticles containing a biologically active agent
DE69429820T3 (de) * 1993-11-19 2013-02-28 Alkermes Controlled Therapeutics, Inc. Herstellung biologisch abbaubarer, einen biologisch aktiven stoff enthaltender, mikropartikel
SG47445A1 (en) * 1993-11-19 1998-04-17 Janssen Pharmaceutica Nv Microencapsulated 3-piperidinyl-substituted1 1 2-benzisoxazoles and 1 2-benzisothiazoles
KR100304179B1 (ko) * 1995-06-06 2001-11-22 게리 디. 스트리트, 스티븐 엘. 네스비트 항정신병제로서의벤즈이속사졸및인다졸유도체,이의제조방법및이를함유하는약제학적조성물
US5792477A (en) * 1996-05-07 1998-08-11 Alkermes Controlled Therapeutics, Inc. Ii Preparation of extended shelf-life biodegradable, biocompatible microparticles containing a biologically active agent

Also Published As

Publication number Publication date
HU224025B1 (hu) 2005-05-30
NO2011015I2 (no) 2013-03-11
BG102443A (en) 1999-06-30
SK284013B6 (sk) 2004-08-03
NO2011015I1 (no) 2011-09-19
AU2955997A (en) 1997-12-09
HK1017852A1 (en) 1999-12-03
KR19990067603A (ko) 1999-08-25
EE9800136A (et) 1998-10-15
SK62098A3 (en) 2000-04-10
AU715572B2 (en) 2000-02-03
UA61898C2 (en) 2003-12-15
DE69708284T2 (de) 2002-07-25
CN1206347A (zh) 1999-01-27
FR11C0035I1 (cs) 2011-07-10
MX9804816A (es) 1998-10-31
ATE208619T1 (de) 2001-11-15
BR9706824B8 (pt) 2015-02-18
IL124551A0 (en) 1998-12-06
JP2000513718A (ja) 2000-10-17
EP0904081B1 (en) 2001-11-14
HUP9901319A2 (hu) 1999-08-30
SI0904081T1 (en) 2002-04-30
NO981984L (no) 1998-11-19
BR9706824A (pt) 1999-03-23
DE122011100027I1 (de) 2011-11-17
CY2011011I2 (el) 2016-12-14
TR199800923T2 (xx) 1999-09-21
LU91842I2 (fr) 2011-09-20
CY2270B1 (en) 2003-07-04
NO981984D0 (no) 1998-04-30
AR007194A1 (es) 1999-10-13
NZ330369A (en) 2000-04-28
FR11C0035I2 (fr) 2013-08-16
ID16927A (id) 1997-11-20
CN1093762C (zh) 2002-11-06
PL327995A1 (en) 1999-01-04
BG62684B1 (bg) 2000-05-31
HRP970276B1 (en) 2002-04-30
DE69708284D1 (de) 2001-12-20
KR100358373B1 (ko) 2003-02-11
US6077843A (en) 2000-06-20
EA000536B1 (ru) 1999-10-28
PL188309B1 (pl) 2005-01-31
MY126302A (en) 2006-09-29
CZ140198A3 (cs) 1999-04-14
DK0904081T3 (da) 2002-02-25
PT904081E (pt) 2002-04-29
WO1997044039A1 (en) 1997-11-27
CZ291284B6 (cs) 2003-01-15
HUP9901319A3 (en) 1999-11-29
EP0904081A1 (en) 1999-03-31
CA2236691C (en) 2007-01-02
ES2167745T3 (es) 2002-05-16
CA2236691A1 (en) 1997-11-27
CY2011011I1 (el) 2016-12-14
JP3274687B2 (ja) 2002-04-15
EA199800531A1 (ru) 1998-12-24
HUS1100013I1 (hu) 2017-03-28
EE03594B1 (et) 2002-02-15
NO315931B1 (no) 2003-11-17
HRP970276A2 (en) 1998-04-30
ZA974331B (en) 1998-11-19
TW487572B (en) 2002-05-21

Similar Documents

Publication Publication Date Title
IL124551A (en) Pharmaceutical depot formulations comprising aqueous suspensions of 9-hydroxy risperidone fatty acid esters
NZ503295A (en) Aqueous pharmaceutical suspensions of submicron 9-hydroxyrisperidone fatty acid esters
HUP0101653A3 (en) Fatty acid derivatives of bile acids and bile acid derivatives and pharmaceutical compositions thereof
ZA929147B (en) Fatty acid esters of alkoxylated isethionic acid
IL147556A0 (en) Pharmaceutical and nutritional compositions containing essential fatty acids and homocysteine-lowering agents
PL331700A1 (en) Method of obtaining fatty acid esters
ZA938947B (en) Fatty acid derivatives and pharmaceutical compositions containing them
AU2111095A (en) Salts of omega-3-polyunsaturated fatty acids and pharmaceutical formulations containing them
AU4560297A (en) Pharmaceutical microspheres of valproic acid for oral administration
IL115594A0 (en) Preparation of alpha-tertiary carboxylic acid esters
HUP9700810A3 (en) Acids and esters of diosmetin and pharmaceutical compositions containing them
AU6557800A (en) Process for the preparation of substituted 3-phenyl-propanoic acid esters and substituted 3-phenyl-propanoic acids
AU6557700A (en) Process for the preparation of substituted 3-phenyl-propanoic acid esters and substituted 3-phenyl-propanoic acids
IL122919A (en) Preparation of 1-alkyl-pyrazole-5- carboxylic acid esters
AU6498298A (en) Mixtures of alkylphosphoric acid esters and their use as cosmetic and pharmaceutical emulsifiers
NZ223684A (en) Guanidine carboxylic acid esters and pharmaceutical compositions
IL153752A0 (en) Preparation of dicarboxylic acid monoesters from cyanocarboxylic acid esters

Legal Events

Date Code Title Description
KB Patent renewed
KB Patent renewed
KB Patent renewed
KB Patent renewed
KB Patent renewed
EXP Patent expired